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A ccumulating research suggests thatlow 25-hydroxyv i t amin D3[25(OH)D] concentrations may be
inversely associated with type 2 diabetes
(1–3), metabolic syndrome (4,5), insulin
resistance (6), and cardiovascular disease
(CVD) (7).
Much remains to be learned, how-
ever, about the relationships between vi-
tamin D status, metabolic syndrome, and
CVD. Furthermore, the published data in
humans arguing that hypovitaminosis D
is a CVD risk factor remain conflicting
(8,9).
Because this topic has received scant
attention and the available information on
associations between vitamin D status and
CVD among type 2 diabetic adults was
lacking, we examined the relationships
between serum 25(OH)D concentrations
and prevalent CVD in type 2 diabetic
adults.
RESEARCH DESIGN AND
METHODS— We studied 459 con-
secutive type 2 diabetic outpatients at-
tending our clinic after exclusion of those
with recent acute illness or advanced
chronic liver or renal disease and those
who were taking medications known to
alter vitamin D metabolism. The control
group consisted of 459 (64% men, age
61 6 years) age- and sex-matched non-
diabetic volunteers.
Biochemical blood measurements
were determined by standard laboratory
procedures. Serum 25(OH)D concentra-
tions were measured during winter
months using an automated chemilumi-
nescence immunoassay (DiaSorin Liai-
son). Metabolic syndrome was defined
according to the Adult Treatment Panel
III criteria (10). Presence of coronary
(myocardial infarction, angina, or revas-
cularization procedures), cerebrovascular
(ischemic stroke, recurrent transient isch-
emic attacks, or carotid endarterectomy),
and peripheral (claudication, lower-
extremity amputation, or revasculariza-
tion procedures) vascular disease was
confirmed by chart review, medical his-
tory and examination, and vascular labo-
ratory studies.
Data are means  SD or frequencies.
Skewed variables were logarithmically
transformed to improve normality before
analysis. Statistical analyses included un-
paired t test, 2 test, and logistic regres-
sion analysis. In this latter analysis, CVD
was considered as an aggregate end point
inclusive of patients with at least one ath-
erosclerotic manifestation. In fully ad-
justed logistic regression models, sex, age,
BMI, smoking, diabetes duration, HbA1c
(A1C), LDL cholesterol, calcium, creati-
nine, albumin excretion rate, use of med-
ications, metabolic syndrome, and
inflammatory markers (fibrinogen or C-
reactive protein [CRP]) were also in-
cluded as covariates. Hypovitaminosis D
was defined as a serum 25(OH)D concen-
tration 20 ng/ml (6,11,12).
RESULTS— The mean (SD) 25 (OH)
D concentration was 24.1  9.1 ng/ml
(median 22.3, range 4.9–91.0) among
control subjects and 19.7 10 ng/ml (17,
3–76) among diabetic patients. The age-
and sex-adjusted prevalence of hypovita-
minosis D was higher in diabetic patients
than in control subjects (60.8 vs. 42.8%,
P  0.001).
As shown in Table 1, diabetic patients
with hypovitaminosis D were more likely
to be women and had increased preva-
lence of higher values of A1C, triglycer-
ides, CRP, and fibrinogen than their
vitamin D–sufficient counterparts. The
proportion using insulin, lipid-lowering,
or antiplatelet drugs was higher among
those with hypovitaminosis D, whereas
the proportion using hypoglycemic drugs
was similar in both groups. Age, BMI,
waist circumference, diabetes duration,
smoking, LDL cholesterol, creatinine, cal-
cium, albuminuria, and metabolic syn-
drome components did not differ
between the groups.
Overall, 143 (31.1%) of 459 patients
were coded positive for CVD. Of these, 81
patients had coronary heart disease, 51
had cerebrovascular disease, and 41 had
peripheral vascular disease; many sub-
jects had CVD in multiple sites. As shown
in Table 1, the prevalence of CVD was
greater among those with hypovitamino-
sis D. Similarly, 25(OH)D was lower (P
0.01) among those with CVD (17.9  9
vs. 20.6  10 ng/ml), coronary disease
(17  9 vs. 20.3  10 ng/ml), and cere-
brovascular disease (16.9 7 vs. 20 10
ng/ml) than among those without CVD.
In logistic regression analysis, the as-
sociation between hypovitaminosis D and
prevalent CVD (odds ratio 1.70 [95% CI
1.1–2.6], P 0.01) remained statistically
significant after adjustment for classical
risk factors, A1C, metabolic syndrome,
renal function tests, calcium, and use of
medications (1.77 [1.1–2.9], P 0.023);
additional adjustment for fibrinogen (or
CRP) levels abolished this association
(1.43 [0.9–2.3], P NS). Almost identi-
cal results were obtained in models that
included the individual components of
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metabolic syndrome and in models in
which a more restrictive threshold to de-
fine hypovitaminosis D (15 ng/ml) was
used (13).
CONCLUSIONS— We found a high
prevalence of hypovitaminosis D and a
strong inverse association between
25(OH)D concentrations and prevalent
CVD among type 2 diabetic outpatients.
Interestingly, our data suggest that the
putative elevated CVD risk associated
with hypovitaminosis D is probably me-
diated by correlated elevations in plasma
inflammatory markers. Moreover, since
elevations of CRP and fibrinogen levels
increase the risk for CVD (14), these find-
ings could help to explain the CVD excess
typically observed during winter months,
a period in which vitamin D status tends
to be poor (15), and suggest a rationale for
vitamin D supplementation in prevention
of CVD, especially in the elderly.
Our findings are supported by few
available data in humans showing that
25(OH)D levels are inversely related to
coronary artery calcifications (16,17) and
are lower in patients with myocardial in-
farction (7) and by experimental studies
(18–22) suggesting that low 25(OH)D in-
fluences the activity/expression of macro-
phages and lymphocytes in atherosclerotic
plaques, thus promoting chronic inflamma-
tion in the artery wall. Interestingly, in two
recent clinical trials (23,24), vitamin D sup-
plementation markedly reduced serum lev-
els of CRP, interleukin-6, and tissue matrix
metalloproteinases. Additionally, low vi-
tamin D3 concentrations result in eleva-
tions of parathyroid hormone, which has
been linked to insulin resistance and sig-
nificant increases in the serum levels of
many acute-phase proteins (25).
Evidently, these findings are all con-
sistent with the proposition that hypovi-
taminosis D and subsequent secondary
hyperparathyroidism may promote the
acute phase response and may help to ex-
plain how hypovitaminosis D might act as
a risk factor for CVD.
This study has some limitations. Be-
cause our study was a cross-sectional one,
the causative nature of the associations
cannot be established. Additionally, para-
thyroid hormone and 1,25(OH)D were
not measured in this study. Further inves-
tigation is necessary to evaluate whether
hypovitaminosis D is associated with in-
cident CVD among type 2 diabetic adults
and to determine possible mechanisms of
any preventive effect from vitamin D sup-
plementation against CVD.
References
1. Boucher BJ, Mannan N, Noonan K, Hales
CN, Evans SJ: Glucose intolerance and
impairment of insulin secretion in rela-
tion to vitamin D deficiency in East Lon-
don Asians. Diabetologia 38:1239–1245,
1995
2. Isaia G, Giorgino R, Adami S: High prev-
alence of hypovitaminosis D in female
type 2 diabetic population (Letter). Dia-
betes Care 24:1496, 2001
3. Scragg R, Sowers M, Bell C: Serum 25-
hydroxyvitamin D, diabetes, and ethnic-
ity in the Third National Health and
Nutrition Examination Survey. Diabetes
Care 27:2813–2818, 2004
4. Boucher BJ: Inadequate vitamin D status:
does it contribute to the disorders com-
prising syndrome X? Br J Nutr 79:315–
327, 1998
5. Ford ES, Ajani UA, McGuire LC, Liu S:
Concentrations of serum vitamin D and
the metabolic syndrome among U.S.
adults. Diabetes Care 28:1228–1230,
2005
6. Chiu KC, Chu A, Go VL, Saad MF: Hypo-
vitaminosis D is associated with insulin
resistance and beta cell dysfunction. Am J
Clin Nutr 79:820–825, 2004
7. Scragg R, Jackson R, Holdaway I, Lim T,
Beaglehole R: Myocardial infarction is in-
versely associated with plasma 25-hy-
droxyvitamin D3 levels: a community-
based study. Int J Epidemiol 19: 559–563,
1990
8. Holick MF: Vitamin D: importance in the
prevention of cancers, type 1 diabetes,
heart disease, and osteoporosis. Am J Clin
Nutr 79:362–371, 2004
Table 1—Baseline characteristics of the study participants, grouped according to vitamin D
status
Variables
Without
hypovitaminosis D
25(OH)D:
29.0  9 ng/ml
With
hypovitaminosis D
25(OH)D:
13.6  3.3 ng/ml P
n 180 279 —
Sex (% men) 74 57 0.001
Age (years) 61  7 62  7 NS
BMI (kg/m2) 29.2  4.5 29.7  5.1 NS
Waist circumference (cm) 106.8  12 107  12 NS
Diabetes duration (years) 11  8 12  8 NS
Diet only (%) 17 14 NS
Oral hypoglycemic agents only (%) 64 57 NS
Insulin treatment (%) 19 29 0.01
Statin users (%) 20.6 31.2 0.01
Aspirin users (%) 20.6 33.7 0.01
Current smokers (%) 16.7 19.7 NS
Systolic blood pressure (mmHg) 144  18 145  17 NS
Diastolic blood pressure (mmHg) 80  7 80  8 NS
A1C (%) 7.0  1.3 7.4  1.3 0.01
(ln)triglycerides (mmol/l) 1.74  0.8 2.02  1.3 0.01
HDL cholesterol (mmol/l) 1.33  0.3 1.36  0.4 NS
LDL cholesterol (mmol/l) 3.49  0.9 3.40  0.9 NS
Creatinine (mol/l) 74  15 76  18 NS
Calcium (mmol/l) 2.35  0.1 2.38  0.2 NS
Fibrinogen (g/l) 4.02  0.9 4.56  0.9 0.001
(ln)hs-CRP (mg/l) 3.85  5.4 5.10  6.7 0.001
Microalbuminuria (%) 18 18.4 NS
Macroalbuminuria (%) 5.8 6.5 NS
Adult Treatment Panel III: metabolic
syndrome (%)
78.7 84.2 NS
Cardiovascular disease (%)
“Aggregate” end point 24.4 35.5 0.01
Coronary 9.5 22.9 0.001
Cerebrovascular 7.8 13.5 0.06
Peripheral 9.9 8.0 NS
Data are the means  SD, unless otherwise indicated. Differences were assessed by the unpaired t test (for
normally distributed variables) and by the 2 test (for categorical variables).
Cigolini and Associates
DIABETES CARE, VOLUME 29, NUMBER 3, MARCH 2006 723
9. Norman PE, Powell JT: Vitamin D, shed-
ding light on the development of disease
in peripheral arteries. Arterioscler Thromb
Vasc Biol 25:39–46, 2005
10. National Cholesterol Education Program:
Executive summary of the third report of
the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment
Panel III). JAMA 285:2486–2497, 2001
11. Fuleihan GE, Deeb M: Hypovitaminosis D
in a sunny country. N Engl J Med 340:
1840–1841, 1999
12. Looker AC, Dawson-Hughes B, Calvo MS,
Gunter EW, Sahyoun NR: Serum 25-hy-
droxyvitamin D status of adolescents and
adults in two seasonal subpopulations
from NHANES III. Bone 30:771–777, 2002
13. Thomas MK, Lloyd-Jones DM, Thadhani
RI, Shaw AC, Deraska DJ, Kitch BT, Vam-
vakas EC, Dick IM, Prince RL, Finkelstein
JS: Hypovitaminosis D in medical inpa-
tients. N Engl J Med 338:777–783, 1998
14. Willerson JT, Ridker PM: Inflammation as
a cardiovascular risk factor. Circulation
109 (Suppl. 1):2–10, 2004
15. Pell JP, Cobbe SM: Seasonal variations in
coronary heart disease.QJM 92:689–696,
1999
16. Doherty T, Tang W, Dascolas S, Watson
KE, Demer LL, Shavelle R, Detrano R:
Ethnic origin and serum levels of 1,25-
dihydroxyvitamin D3 are independent
predictors of coronary calcium mass mea-
sured by electron-beam computed to-
mography. Circulation 96:1477–1481,
1997
17. Watson KE, Abrolat ML, Malone LL, Hoeg
JM, Doherty T, Detrano R, Demer LL: Ac-
tive serum vitamin D levels are inversely
correlated with coronary calcification.
Circulation 96:1755–1760, 1997
18. Brown A, Dusso A, Slatopolsky E: Vitamin
D. Am J Physiol 277:F157–F175, 1999
19. Barsony J, Prufer K: Vitamin D receptors
and retinoid X receptors interactions in
motion. Vitam Horm 65:345–376, 2002
20. Pierce R, Kolodzie M, Parks W: 1,25-di-
hydroxyvitamin D3 repress tropoelastin
expression by a posttranscriptional mech-
anism. J Biol Chem 267:11593–11599,
1992
21. Veldman C, Cantorna M, DeLuca H: Ex-
pression of 1,25 dihydroxyvitamin D3 re-
ceptor in the immune system. Arch
Biochem Biophys 374:334–338, 2000
22. Willheim M, Thien R, Schrattbauer K,
Bajna E, Holub M, Gruber R, Baier K,
Pietschmann P, Reinisch W, Scheiner O,
Peterlik M: Regulatory effects of 1alpha,
25 dihydroxyvitamin D3 on the cytokine
production of human peripheral blood
lymphocytes. J Clin Endocrinol Metab 84:
3739–3744, 1999
23. Van den Berghe G, Van Roosbroeck D,
Vanhove P, Wouters PJ, De Pourcq L,
Bouillon R: Bone turnover in prolonged
critical illness: effect of vitamin D. J Clin
Endocrinol Metab 88:4623–4632, 2003
24. Timms PM, Mannan N, Hitman GA,
Noonan K, Mills PG, Syndercombe-Court
D, Aganna E, Price CP, Boucher BJ: Cir-
culating MMP9, vitamin D and variation
in the TIMP-1 response with VDR geno-
type: mechanisms for inflammatory dam-
age in chronic disorders? QJM 95:787–
796, 2002
25. McCarty MF: Secondary hyperparathy-
roidism promotes the acute phase respon-
se:a rationale for supplemental vitamin D
in prevention of vascular events in the el-
derly. Med Hypotheses 64:1022–1026,
2005
Vitamin D status and CVD in diabetes
724 DIABETES CARE, VOLUME 29, NUMBER 3, MARCH 2006
